CY1118447T1 - Fc ΜΕΤΑΛΛΑΓΜΑΤΑ ΑΝΤΙΣΩΜΑΤΩΝ ΜΕ ΑΦΑΙΡΕΘΕΙΣΕΣ ΤΕΛΕΣΤΙΚΕΣ ΛΕΙΤΟΥΡΓΙΕΣ - Google Patents
Fc ΜΕΤΑΛΛΑΓΜΑΤΑ ΑΝΤΙΣΩΜΑΤΩΝ ΜΕ ΑΦΑΙΡΕΘΕΙΣΕΣ ΤΕΛΕΣΤΙΚΕΣ ΛΕΙΤΟΥΡΓΙΕΣInfo
- Publication number
- CY1118447T1 CY1118447T1 CY20171100054T CY171100054T CY1118447T1 CY 1118447 T1 CY1118447 T1 CY 1118447T1 CY 20171100054 T CY20171100054 T CY 20171100054T CY 171100054 T CY171100054 T CY 171100054T CY 1118447 T1 CY1118447 T1 CY 1118447T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibody
- mutuals
- telephone functions
- removable telephone
- removable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
Abstract
Αντίσωμα και άλλα μόρια που περιέχουν Fc, με παραλλαγές στην Fc περιοχή μειώνουν πρόσδεση σε Fc γάμμα υποδοχείς και προκύπτουσα δραστικότητα και μπορούν να χρησιμοποιηθούν στην θεραπευτική αγωγή διαφόρων ασθενειών και διαταραχών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26507909P | 2009-11-30 | 2009-11-30 | |
PCT/US2010/058188 WO2011066501A1 (en) | 2009-11-30 | 2010-11-29 | Antibody fc mutants with ablated effector functions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118447T1 true CY1118447T1 (el) | 2017-06-28 |
Family
ID=44066941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100054T CY1118447T1 (el) | 2009-11-30 | 2017-01-17 | Fc ΜΕΤΑΛΛΑΓΜΑΤΑ ΑΝΤΙΣΩΜΑΤΩΝ ΜΕ ΑΦΑΙΡΕΘΕΙΣΕΣ ΤΕΛΕΣΤΙΚΕΣ ΛΕΙΤΟΥΡΓΙΕΣ |
Country Status (24)
Country | Link |
---|---|
US (3) | US8961967B2 (el) |
EP (2) | EP3141260B1 (el) |
JP (3) | JP5784624B2 (el) |
KR (1) | KR101791430B1 (el) |
CN (1) | CN102711810B (el) |
AU (1) | AU2010324684B2 (el) |
BR (1) | BR112012013038A2 (el) |
CA (1) | CA2782218C (el) |
CY (1) | CY1118447T1 (el) |
DK (1) | DK2506871T3 (el) |
EA (2) | EA201890907A1 (el) |
ES (2) | ES2751549T3 (el) |
HR (1) | HRP20161542T1 (el) |
HU (1) | HUE032872T2 (el) |
IL (2) | IL219864A (el) |
LT (1) | LT2506871T (el) |
ME (1) | ME02568B (el) |
MX (1) | MX2012006243A (el) |
PL (1) | PL2506871T3 (el) |
PT (1) | PT2506871T (el) |
RS (1) | RS55460B1 (el) |
SI (1) | SI2506871T1 (el) |
SM (1) | SMT201600387B (el) |
WO (1) | WO2011066501A1 (el) |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE032025T2 (en) | 2008-01-31 | 2017-08-28 | Inserm - Inst Nat De La Sante Et De La Rech Medicale | Antibodies to human CD39 and their use to inhibit regulatory T cell activity |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US8932256B2 (en) | 2009-09-02 | 2015-01-13 | Medtronic Minimed, Inc. | Insertion device systems and methods |
US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
WO2011066501A1 (en) * | 2009-11-30 | 2011-06-03 | Centocor Ortho Biotech Inc. | Antibody fc mutants with ablated effector functions |
AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
EP2699256B1 (en) | 2011-04-21 | 2017-09-27 | The Regents of the University of Colorado, a body corporate | Compositions and methods for the treatment of neuromyelitis optica |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
AU2012311286B2 (en) | 2011-09-19 | 2018-07-26 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
CA2862448A1 (en) * | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
JP2015512635A (ja) | 2012-03-28 | 2015-04-30 | カイマブ・リミテッド | クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物 |
US9090694B2 (en) * | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
PL3434695T3 (pl) * | 2012-08-07 | 2021-05-17 | Roche Glycart Ag | Ulepszona immunoterapia |
EP3447069B1 (en) | 2012-11-21 | 2020-09-23 | Janssen Biotech, Inc. | Bispecific egfr/c-met antibodies |
US20150329640A1 (en) * | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
DK2943511T3 (da) | 2013-01-14 | 2019-10-21 | Xencor Inc | Nye heterodimeriske proteiner |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
CN105229032A (zh) | 2013-03-18 | 2016-01-06 | 比奥塞罗克斯产品公司 | 人源化抗cd134(ox40)抗体及其应用 |
ES2736326T3 (es) | 2013-05-31 | 2019-12-27 | Zymeworks Inc | Heteromultímeros con función efectora reducida o silenciada |
IL290613B1 (en) | 2013-07-05 | 2024-07-01 | Genmab As | CD3 antibodies of human origin or chimeras |
WO2015035606A1 (en) * | 2013-09-13 | 2015-03-19 | Beigene, Ltd. | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
LT3065774T (lt) | 2013-11-06 | 2021-09-10 | Janssen Biotech, Inc. | Anti-ccl17 antikūnai |
MX2016006301A (es) | 2013-11-13 | 2016-12-16 | Zymeworks Inc | Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos. |
JP6817064B2 (ja) | 2013-11-27 | 2021-01-20 | ザイムワークス,インコーポレイテッド | Her2を標的とする二重特異性抗原結合性コンストラクト |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
AU2015243377A1 (en) | 2014-04-11 | 2016-09-15 | Medimmune, Llc | Bispecific HER2 antibodies |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的NKp46結合タンパク質 |
CA2952532A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
UA123432C2 (uk) | 2014-07-30 | 2021-04-07 | Нджм Біофармасьютікалз, Інк. | Димер та спосіб його застосування для лікування метаболічних розладів |
WO2016036918A1 (en) * | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
WO2016054114A1 (en) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions |
SG11201701341UA (en) | 2014-10-10 | 2017-03-30 | Innate Pharma | Cd73 blockade |
WO2016131950A1 (en) | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
AP2017009828A0 (en) | 2014-10-31 | 2017-03-31 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
PT3218406T (pt) | 2014-11-10 | 2021-06-17 | Medimmune Ltd | Moléculas de ligação específicas para cd73 e seus usos |
US20160129108A1 (en) | 2014-11-11 | 2016-05-12 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and uses thereof |
KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
WO2016081423A1 (en) | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
MX2017006323A (es) | 2014-11-21 | 2017-08-21 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
CN107001474B (zh) | 2014-11-21 | 2021-10-01 | 百时美施贵宝公司 | 抗cd73抗体及其用途 |
AU2015353409B2 (en) | 2014-11-26 | 2019-05-09 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
US9382321B2 (en) | 2014-11-26 | 2016-07-05 | Adventis Health System/Sunbelt, Inc. | Effector-deficient anti-CD32A antibodies |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EP3223848A4 (en) | 2014-11-27 | 2018-07-18 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
CA3022547A1 (en) * | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
CA2990511A1 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific antigen binding proteins |
AU2016284871B2 (en) | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
GB201513033D0 (en) * | 2015-07-23 | 2015-09-09 | Ucb Biopharma Sprl | Proteins |
CN114605549A (zh) | 2015-08-05 | 2022-06-10 | 詹森生物科技公司 | 抗cd154抗体及其使用方法 |
RU2740672C2 (ru) * | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
GB201515745D0 (en) * | 2015-09-04 | 2015-10-21 | Ucb Biopharma Sprl | Proteins |
EP3362475B1 (en) | 2015-10-12 | 2023-08-30 | Innate Pharma | Cd73 blocking agents |
EP4046655A1 (en) | 2015-11-03 | 2022-08-24 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
IL259585B1 (en) | 2015-11-25 | 2024-07-01 | Visterra Inc | Antibody molecules to APRIL and their uses |
CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
US20180355043A1 (en) | 2015-12-17 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies Specifically Binding HLA-DR and Their Uses |
EA038880B1 (ru) | 2016-01-11 | 2021-11-01 | Форти Севен, Инк. | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 |
JP7270379B2 (ja) | 2016-03-08 | 2023-05-10 | イナート・ファルマ・ソシエテ・アノニム | Siglec中和抗体 |
US20190071514A1 (en) | 2016-03-14 | 2019-03-07 | Innate Pharma | Anti-cd39 antibodies |
TW201808987A (zh) | 2016-06-08 | 2018-03-16 | 健生生物科技公司 | Gm-csf變體及使用方法 |
IL263542B1 (en) | 2016-06-14 | 2024-06-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
US10316088B2 (en) | 2016-06-28 | 2019-06-11 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
UA128304C2 (uk) | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Мультиспецифічне антитіло до cd40 і cd137 |
US20180044430A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them |
US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
US11254753B2 (en) * | 2016-10-06 | 2022-02-22 | Glaxosmithkline Intellectual Property Development Limited | Antibodies with reduced binding to process impurities |
BR112019007288A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente |
EP3532497B1 (en) * | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
WO2018083080A2 (en) | 2016-11-04 | 2018-05-11 | Innate Pharma | Nkp46 ligand |
WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
WO2018162749A1 (en) | 2017-03-09 | 2018-09-13 | Genmab A/S | Antibodies against pd-l1 |
JP7308150B2 (ja) | 2017-03-16 | 2023-07-13 | イナート・ファルマ・ソシエテ・アノニム | 癌を処置するための組成物及び方法 |
CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
WO2019011855A1 (en) | 2017-07-10 | 2019-01-17 | Innate Pharma | ANTIBODIES NEUTRALIZING SIGLEC-9 |
WO2019011852A1 (en) | 2017-07-10 | 2019-01-17 | Innate Pharma | POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER |
ES2963157T3 (es) | 2017-07-26 | 2024-03-25 | Forty Seven Inc | Anticuerpos anti-SIRP-alfa y métodos relacionados |
KR20200064062A (ko) | 2017-08-04 | 2020-06-05 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
US20190100587A1 (en) * | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗pd−1配列を用いた二重特異性および単一特異性抗体 |
EP3728302A1 (en) | 2017-12-19 | 2020-10-28 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
CN109971723B (zh) * | 2017-12-28 | 2023-07-07 | 上海细胞治疗研究院 | 包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途 |
CA3090489A1 (en) | 2018-02-12 | 2019-08-15 | Forty Seven, Inc. | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies |
US20210260210A1 (en) | 2018-03-13 | 2021-08-26 | Zymeworks Inc. | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
IT201800004853A1 (it) | 2018-04-24 | 2019-10-24 | Metodi per trattare il cancro | |
EA202092518A1 (ru) | 2018-06-18 | 2021-08-23 | Иннейт Фарма | Композиции и способы лечения рака |
TW202016144A (zh) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
AU2019331024A1 (en) | 2018-08-31 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies |
CN113195523A (zh) | 2018-10-03 | 2021-07-30 | Xencor股份有限公司 | IL-12异源二聚体Fc融合蛋白 |
US20220025056A1 (en) | 2018-12-26 | 2022-01-27 | Innate Pharma | Leucocyte immunoglobulin-like receptor neutralizing antibodies |
JP7520848B2 (ja) | 2018-12-28 | 2024-07-23 | スパークス・セラピューティクス・インコーポレイテッド | 癌および他の疾患の治療のための、クローディン18.2に特異的な結合分子、その組成物および方法 |
CN111217915B (zh) * | 2019-01-08 | 2021-05-14 | 东莞太力生物工程有限公司 | GLP-1类似物Fc融合多肽及其应用 |
CA3131033A1 (en) | 2019-02-22 | 2020-08-27 | Wuhan Yzy Biopharma Co., Ltd. | Modified fc fragment, antibodies containing the same and use thereof |
JP2022523946A (ja) | 2019-03-01 | 2022-04-27 | ゼンコア インコーポレイテッド | Enpp3およびcd3に結合するヘテロ二量体抗体 |
CA3136698A1 (en) | 2019-04-23 | 2020-10-29 | Innate Pharma | Cd73 blocking antibodies |
WO2020243338A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
KR20220053578A (ko) * | 2019-08-02 | 2022-04-29 | 아케소 파마슈티컬스, 인코포레이티드 | 항-ctla4/항-pd-1 이중특이성 항체 및 그의 용도 |
GB201912437D0 (en) | 2019-08-30 | 2019-10-16 | Glaxosmithkline Ip Dev Ltd | CR2 Binding Proteins and their use in Medical Therapy |
CN115066274A (zh) | 2019-09-25 | 2022-09-16 | 斯图加特大学 | 三价结合分子 |
TW202140553A (zh) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
WO2021234160A2 (en) | 2020-05-22 | 2021-11-25 | Formycon Ag | Ace2 fusion proteins and uses thereof |
WO2022024034A1 (en) | 2020-07-31 | 2022-02-03 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding protein |
AU2021322046A1 (en) | 2020-08-06 | 2023-02-02 | BioNTech SE | Binding agents for coronavirus S protein |
EP4196500A2 (en) | 2020-08-13 | 2023-06-21 | Innate Pharma | Cancer treatment methods using anti-cd73 antibodies |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
MX2023002545A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. |
MX2023002546A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpos biespecificos contra cumulo de diferenciacion 3 (cd3) y contra cumulo de diferenciacion 20 (cd20) para tratar leucemia linfocitica cronica. |
EP4204091A2 (en) | 2020-10-29 | 2023-07-05 | Formycon AG | Ace2 fusion proteins and uses thereof |
US11802150B2 (en) | 2020-12-02 | 2023-10-31 | GlaxoSmith Kline Intellectual Property Development Limited | IL-7 binding proteins and their use in medical therapy |
KR20230142831A (ko) | 2021-01-13 | 2023-10-11 | 비스테라, 인크. | 인간화된 보체 5a 수용체 1 항체 및 이의 사용 방법 |
CA3205815A1 (en) | 2021-03-03 | 2022-09-09 | Alwin REITER | Formulations of ace2 fc fusion proteins |
WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
JP2024521187A (ja) | 2021-05-28 | 2024-05-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ガンの治療のための組み合わせ療法 |
EP4412713A1 (en) | 2021-10-05 | 2024-08-14 | GlaxoSmithKline Intellectual Property Development Ltd | Combination therapies for treating cancer |
WO2023094507A1 (en) | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
WO2023168352A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
WO2023212304A1 (en) | 2022-04-29 | 2023-11-02 | 23Andme, Inc. | Antigen binding proteins |
WO2023227660A1 (en) | 2022-05-25 | 2023-11-30 | Innate Pharma | Nectin-4 binding agents |
WO2023227641A1 (en) | 2022-05-27 | 2023-11-30 | Glaxosmithkline Intellectual Property Development Limited | Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment |
WO2024092038A2 (en) | 2022-10-25 | 2024-05-02 | Ablexis, Llc | Anti-cd3 antibodies |
WO2024107731A2 (en) | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
EP4386084A1 (en) | 2022-12-14 | 2024-06-19 | Formycon AG | Improved ace2 fusion proteins |
WO2024127277A1 (en) | 2022-12-16 | 2024-06-20 | Glaxosmithkline Intellectual Property Development Limited | Method of treating pain with an anti-ccl17 antibody |
WO2024165671A1 (en) | 2023-02-08 | 2024-08-15 | Immunos Therapeutics Ag | FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US7183387B1 (en) * | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
BR0008758A (pt) * | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
CN101014619B (zh) | 2004-07-15 | 2010-11-03 | 赞科股份有限公司 | 优化的Fc变体 |
NZ554725A (en) | 2004-10-25 | 2009-10-30 | Merck & Co Inc | Anti-ADDL antibodies and uses thereof |
US7700099B2 (en) * | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
SI1919503T1 (sl) * | 2005-08-10 | 2015-02-27 | Macrogenics, Inc. | Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
KR20160070165A (ko) | 2008-02-08 | 2016-06-17 | 메디뮨 엘엘씨 | Fc 리간드 친화성이 감소된 항-IFNAR1 항체 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
WO2011066501A1 (en) * | 2009-11-30 | 2011-06-03 | Centocor Ortho Biotech Inc. | Antibody fc mutants with ablated effector functions |
ES2826894T3 (es) | 2010-02-19 | 2021-05-19 | Xencor Inc | Nuevas inmunoadhesinas CTLA4-IG |
US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
EP3447069B1 (en) * | 2012-11-21 | 2020-09-23 | Janssen Biotech, Inc. | Bispecific egfr/c-met antibodies |
WO2014100490A1 (en) | 2012-12-19 | 2014-06-26 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
EP2991679A4 (en) | 2013-04-29 | 2016-12-07 | Adimab Llc | POLYSPECIFIC REAGENTS, PROCESS FOR THEIR PREPARATION AND USE |
CN107001474B (zh) | 2014-11-21 | 2021-10-01 | 百时美施贵宝公司 | 抗cd73抗体及其用途 |
EP4249066A3 (en) | 2014-12-23 | 2023-11-22 | Bristol-Myers Squibb Company | Antibodies to tigit |
EP4046655A1 (en) * | 2015-11-03 | 2022-08-24 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
-
2010
- 2010-11-29 WO PCT/US2010/058188 patent/WO2011066501A1/en active Application Filing
- 2010-11-29 RS RS20160993A patent/RS55460B1/sr unknown
- 2010-11-29 SI SI201031319A patent/SI2506871T1/sl unknown
- 2010-11-29 EA EA201890907A patent/EA201890907A1/ru unknown
- 2010-11-29 BR BR112012013038A patent/BR112012013038A2/pt not_active Application Discontinuation
- 2010-11-29 MX MX2012006243A patent/MX2012006243A/es active IP Right Grant
- 2010-11-29 ES ES16194473T patent/ES2751549T3/es active Active
- 2010-11-29 AU AU2010324684A patent/AU2010324684B2/en active Active
- 2010-11-29 DK DK10834008.4T patent/DK2506871T3/da active
- 2010-11-29 EP EP16194473.1A patent/EP3141260B1/en active Active
- 2010-11-29 EA EA201290413A patent/EA030792B1/ru unknown
- 2010-11-29 CN CN201080055151.7A patent/CN102711810B/zh active Active
- 2010-11-29 US US12/955,240 patent/US8961967B2/en active Active
- 2010-11-29 EP EP10834008.4A patent/EP2506871B1/en active Active
- 2010-11-29 PT PT108340084T patent/PT2506871T/pt unknown
- 2010-11-29 LT LTEP10834008.4T patent/LT2506871T/lt unknown
- 2010-11-29 HU HUE10834008A patent/HUE032872T2/en unknown
- 2010-11-29 JP JP2012541220A patent/JP5784624B2/ja active Active
- 2010-11-29 ES ES10834008.4T patent/ES2609043T3/es active Active
- 2010-11-29 PL PL10834008T patent/PL2506871T3/pl unknown
- 2010-11-29 CA CA2782218A patent/CA2782218C/en active Active
- 2010-11-29 KR KR1020127016646A patent/KR101791430B1/ko active IP Right Grant
- 2010-11-29 ME MEP-2016-261A patent/ME02568B/me unknown
-
2012
- 2012-05-17 IL IL219864A patent/IL219864A/en active IP Right Grant
-
2015
- 2015-01-15 US US14/597,690 patent/US9637549B2/en active Active
- 2015-07-22 JP JP2015144573A patent/JP2015232009A/ja active Pending
-
2016
- 2016-10-27 SM SM201600387T patent/SMT201600387B/it unknown
- 2016-11-21 HR HRP20161542TT patent/HRP20161542T1/hr unknown
- 2016-12-27 JP JP2016252445A patent/JP2017095479A/ja active Pending
-
2017
- 2017-01-17 CY CY20171100054T patent/CY1118447T1/el unknown
- 2017-02-08 IL IL250508A patent/IL250508A0/en unknown
- 2017-03-20 US US15/463,716 patent/US20170204193A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118447T1 (el) | Fc ΜΕΤΑΛΛΑΓΜΑΤΑ ΑΝΤΙΣΩΜΑΤΩΝ ΜΕ ΑΦΑΙΡΕΘΕΙΣΕΣ ΤΕΛΕΣΤΙΚΕΣ ΛΕΙΤΟΥΡΓΙΕΣ | |
CY1117859T1 (el) | Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης | |
CY1118923T1 (el) | ΔΡΑΣΤΙΚΑ ΜΕΤΑΛΛΑΓΜΑΤΑ Fc ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΘΕΚΤΙΚΑ ΣΕ ΠΡΩΤΕΑΣΕΣ | |
CY1123079T1 (el) | Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων | |
CY1122020T1 (el) | Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3 | |
CY1112739T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης | |
CY1123030T1 (el) | Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων | |
CY1112912T1 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
CY1124698T1 (el) | Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους | |
EA200900040A1 (ru) | Молекулы антител, которые связываются с человеческим il-17 | |
ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
CR20120105A (es) | Proteínas terapéuticas de unión a dll4 | |
NO20091064L (no) | Antistoffer mot IL-17A | |
EP2285409A4 (en) | IL-1 ALPHA ANTIBODIES AND METHODS OF USE | |
BR112012028764A2 (pt) | anticor-pos antifgfr2 | |
MY157173A (en) | Modified humanised anti-interleukin-18 | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
CY1117942T1 (el) | Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april) | |
EA200801427A1 (ru) | Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека | |
EA202192165A1 (ru) | Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы | |
BR112012013876A2 (pt) | proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos | |
MA32754B1 (fr) | Molécule de liaison à l'antigène capable de se lier à deux molécules d'antigène ou plus de manière répétée | |
ATE469658T1 (de) | Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung | |
AR051925A1 (es) | Anticuerpos anti-ox4ol | |
CR11179A (es) | Anticuerpos humanizados contra el globometro ab (20-42) y sus usos |